By now, you've probably heard the word "semaglutide" more than a few times — from your provider, a friend, a social media feed, or a late-night news segment. Interest in GLP-1 therapy for weight management has grown significantly over the past few years, and with it, a lot of questions. One of the most common: Is there an option other than injections?
Sublingual semaglutide is a compounded delivery format that has been generating genuine clinical interest. Rather than an injectable, it's a formulation designed to be absorbed under the tongue — a method called sublingual administration. It's not a commercial product like Ozempic or Rybelsus. It's a patient-specific, compounded medication prepared by a licensed pharmacist based on a prescription from your healthcare provider.
This guide was written by the pharmacist team at Potter's House Apothecary to help you understand what sublingual semaglutide actually is, how it compares to other delivery formats, what the research says, and what to expect if your provider determines it may be appropriate for your health goals.
What Is Sublingual Semaglutide?
Sublingual semaglutide is a compounded formulation of semaglutide — a GLP-1 receptor agonist — designed to be absorbed through the mucous membranes beneath the tongue rather than injected under the skin or swallowed as a tablet.
To understand why that matters, it helps to start with GLP-1 itself. GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone released in your gut after you eat. It plays several important roles: it signals your brain that you're full, slows gastric emptying, and helps regulate blood sugar by stimulating insulin release. Semaglutide mimics this hormone, binding to the same receptors and producing similar effects.
When semaglutide is delivered sublingually, it's held under the tongue for a period of time and absorbed directly into the bloodstream through the oral mucosa — the thin, highly vascular tissue that lines the mouth. This route bypasses the digestive tract, which can be significant for peptide-based compounds that may be broken down before reaching the bloodstream if swallowed.
It's important to be clear about what sublingual semaglutide is not. It is not Ozempic. It is not Rybelsus. It is not an FDA-approved product. It is a compounded, patient-specific medication — prepared by a licensed 503A compounding pharmacy based on an individual prescription from a licensed healthcare provider. Compounding allows pharmacists to customize delivery routes and concentrations to meet the unique needs of individual patients when commercially available products may not be the right fit.
How Is Sublingual Semaglutide Different from Ozempic and Rybelsus?
If you've done any research on semaglutide, you've likely encountered the names Ozempic, Wegovy, and Rybelsus. Here's how the delivery routes differ:
- Ozempic / Wegovy — Subcutaneous injection. A small needle is used to deliver the medication into the fatty tissue just beneath the skin, typically in the abdomen, thigh, or upper arm. These are FDA-approved commercial medications.
- Rybelsus — An oral tablet that is swallowed. It uses a specialized absorption enhancer (SNAC) to allow the semaglutide molecule to survive the digestive environment and be absorbed through the stomach lining. Also an FDA-approved commercial product.
- Compounded sublingual semaglutide — A liquid or troche formulation held under the tongue, absorbed through the oral mucosa. This is a compounded formulation — not FDA approved, patient-specific, and prepared by a licensed compounding pharmacist per your provider's prescription.
Each of these delivery methods produces a different pharmacokinetic profile — meaning how the medication is absorbed, distributed, and cleared by the body can vary. For sublingual formulations specifically, the oral mucosal absorption pathway avoids first-pass metabolism through the liver, which may influence how the compound behaves in the body.
It's worth noting that compared to the injectable and oral tablet forms, sublingual semaglutide is a newer area of clinical investigation. Pharmacokinetic research into sublingual delivery of GLP-1 receptor agonists is ongoing, and it represents an active area of interest in compounding science.
| Format | Route | FDA Status | Rx Required |
|---|---|---|---|
| Ozempic / Wegovy | Subcutaneous injection | FDA approved | Yes |
| Rybelsus | Oral tablet (swallowed) | FDA approved | Yes |
| Compounded sublingual semaglutide | Under the tongue | Not FDA approved | Yes |
What Does the Research Say?
Clinical evidence for semaglutide as a compound class is substantial. Published trials — including the SUSTAIN and STEP trial programs — have demonstrated that semaglutide-based therapies may support meaningful weight reduction and improvements in metabolic markers in adults with overweight or obesity when used alongside dietary and lifestyle modifications. Studies published in The New England Journal of Medicine and indexed on PubMed have reported average weight loss in the range of 10–15% of body weight over 68 weeks in participants using injectable semaglutide, with individual outcomes varying considerably.
For the sublingual route specifically, pharmacokinetic research is still developing. A study published in Drug Delivery explored the single-dose pharmacokinetics of sublingual semaglutide and found measurable absorption via the oral mucosal route, though researchers noted that further investigation is needed to fully characterize its bioavailability profile compared to subcutaneous delivery.
What this means in practical terms: the clinical weight loss data you may see cited in the media is largely based on FDA-approved injectable or oral tablet formulations. Compounded sublingual semaglutide has not been studied at the same scale or in the same independent clinical trials. Your provider and pharmacist can help you understand what the current evidence suggests and what it means for your individual situation.
No two patients are alike — and that's precisely the principle that guides compounding care at Potter's House Apothecary.
What Can You Expect From Compounded Sublingual Semaglutide?
How Is It Taken?
Sublingual semaglutide is typically formulated as a liquid drop or a small troche (a dissolvable lozenge). The medication is placed under the tongue and held there for a prescribed period of time — usually several minutes — to allow absorption through the oral mucosa. It should not be swallowed immediately, as that would route it through the digestive tract rather than directly into the bloodstream.
Your prescribing provider will determine the dosing protocol that is appropriate for your individual needs. Semaglutide-based therapies are typically initiated at a lower dose and gradually titrated upward over time based on tolerability and response — a standard approach in GLP-1 therapy. We do not publish specific dosing information here because dosing is always individualized and should be determined by your healthcare provider.
Does Semaglutide Make You Thirsty?
Some individuals do report increased thirst while taking semaglutide. This is thought to be related in part to how the medication affects appetite and fluid intake patterns — as overall food consumption may decrease, some patients may also drink less, which can contribute to mild dehydration. Additionally, GLP-1 receptor signaling has been studied in relation to fluid and sodium regulation in the body, though the full mechanisms are still being investigated.
If you notice increased thirst, staying well hydrated is generally encouraged. As always, discuss any new or unexpected symptoms with your prescribing provider.
What Are Common Side Effects of Semaglutide?
The most commonly reported side effects with semaglutide — across delivery routes — are gastrointestinal in nature. These may include:
- Nausea (most commonly reported, particularly during dose titration)
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- Bloating or abdominal discomfort
For many patients, these effects are most noticeable when starting or adjusting the dose, and they often improve over time. Not everyone experiences them. Your provider may adjust your dosing schedule to help minimize GI effects during the adjustment period.
More serious adverse effects are possible and should be reviewed thoroughly with your prescribing provider before starting any semaglutide-based therapy. This content is not a substitute for a clinical consultation.
What Kind of Results Can Patients Expect?
Individual results vary significantly depending on starting weight, metabolic factors, dietary habits, physical activity, and overall health status. Semaglutide is not a standalone weight loss solution — it is typically used as part of a medically supervised program that includes lifestyle support.
Research on GLP-1 receptor agonists suggests that some individuals may experience meaningful reductions in body weight over time. However, the average weight loss semaglutide data cited in clinical trials applies to FDA-approved formulations studied in controlled research settings. Outcomes with compounded sublingual formulations have not been independently validated at the same scale.
Results are not guaranteed. Your provider is your best resource for setting realistic expectations based on your individual health profile.
Who May Be a Candidate for Sublingual Semaglutide?
Compounded sublingual semaglutide may be considered by adults who are working with a qualified healthcare provider on medically supervised weight management and who prefer a non-injectable delivery route. Your provider will evaluate whether a GLP-1-based therapy is appropriate based on your health history, current medications, and individual goals.
To receive compounded sublingual semaglutide from Potter's House Apothecary, you will need:
- A valid prescription from a licensed healthcare provider
- To be located in one of our licensed states — Arizona, Colorado, or Montana
- A provider who has reviewed your health history and determined this formulation may be appropriate for you
This is not a medication available over the counter or through self-directed purchase. Compounded medications require a prescriber relationship — and that's by design. Your provider's involvement helps ensure the treatment is matched to your specific clinical needs.
If you're interested in exploring whether sublingual semaglutide might be appropriate for your weight management goals, our team can work alongside your current provider — or help connect you with a consultation. You can also explore our GLP-1 Probiotic Pro, a pharmaceutical-grade supplement designed to support gut health during GLP-1 therapy, and read more about supplements for gut health and bloating that some patients find helpful as a complement to their weight management plan.
Why Choose a PCAB-Accredited Compounding Pharmacy?
Not all compounded GLP-1 formulations are created equal. The quality of a compounded medication depends entirely on the standards, facilities, and expertise of the pharmacy that prepares it. This matters significantly for patient safety.
Potter's House Apothecary is PCAB accredited — a voluntary, rigorous accreditation program through the Pharmacy Compounding Accreditation Board that holds pharmacies to standards that go beyond state licensing requirements. PCAB-accredited pharmacies comply with USP (United States Pharmacopeia) quality standards for both sterile and non-sterile compounding, use pharmaceutical-grade active ingredients, conduct beyond-use dating testing, and undergo regular third-party review.
Our pharmacy has been serving patients in Arizona since 2009. Our team of experienced PharmDs specializes in patient-specific compounding and works collaboratively with prescribers to optimize each patient's therapeutic experience. We are licensed to serve patients in Arizona, Colorado, and Montana, and we take pride in the level of individualized attention each prescription receives.
When you choose Potter's House Apothecary, you're choosing a state-of-the-art facility with the credentials, experience, and commitment to quality that personalized compounding requires. Learn more about our compounding pharmacy services or explore supplement support for menopause-related weight changes as part of a broader wellness approach.
Frequently Asked Questions
Is sublingual semaglutide FDA approved?
No. Compounded sublingual semaglutide is not an FDA-approved medication. It is a patient-specific compounded formulation prepared by a licensed 503A compounding pharmacy based on an individual prescription. Compounded medications are not reviewed by the FDA for safety or efficacy. This is distinct from FDA-approved semaglutide products such as Ozempic, Wegovy, and Rybelsus.
Â
Do I need a prescription for compounded sublingual semaglutide?
Yes. A prescription from a licensed healthcare provider is required for all compounded medications, including sublingual semaglutide. Potter's House Apothecary prepares compounded medications only upon receipt of a valid prescription. Your provider will evaluate whether this formulation is appropriate for your individual health needs.
Â
How long does it take to see results with semaglutide?
Results vary by individual and depend on many factors, including starting weight, diet, activity level, dosing, and overall health. In published clinical trials of FDA-approved semaglutide formulations, meaningful weight changes were typically observed over a period of weeks to months. Individual outcomes with compounded sublingual semaglutide have not been studied at the same scale. Your prescribing provider is the best resource for setting realistic expectations.
Â
Can patients in Colorado or Montana receive compounded sublingual semaglutide from Potter's House Apothecary?
Yes. Potter's House Apothecary is licensed to dispense compounded medications to patients in Arizona, Colorado, and Montana. A valid prescription from a licensed healthcare provider in your state is required.
Â
What is the difference between semaglutide drops and semaglutide tablets like Rybelsus?
Rybelsus is an FDA-approved oral semaglutide tablet that is swallowed and absorbed through the stomach lining using a specialized absorption-enhancing technology. Sublingual semaglutide drops are a compounded formulation that is held under the tongue and absorbed through the oral mucosa — a different absorption pathway. Rybelsus is a commercial pharmaceutical product; sublingual semaglutide is a patient-specific compounded preparation. They are not the same product and have different regulatory statuses.
The Bottom Line
Sublingual semaglutide is a compounded, patient-specific GLP-1 formulation that may be an option for adults working with a qualified provider on medically supervised weight management — particularly those who prefer a non-injectable delivery route. It is not a commercial pharmaceutical product, it is not FDA approved, and it is not right for everyone.
What it can be, for the right patient, is a thoughtfully prepared, pharmacist-guided option that is customized to your individual needs — formulated with precision by a team that has been doing this for more than 15 years.
If you have questions about whether sublingual semaglutide may be appropriate for your health goals, we'd love to help. Our pharmacist team works alongside your provider to make sure you have the information and support you need to make the best decision for your health.
Schedule a Hormone Consultation today →
A prescription from a licensed healthcare provider is required for compounded medications. Compounded medications are not reviewed by the FDA for safety or efficacy. The information provided in this article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult your healthcare provider before starting, stopping, or changing any medication or treatment plan.